MeSH tree: D03.383.533.312
HIV treatment has delivered life-altering advantages. Antiretroviral therapy has led to a reduced mortality and improved life expectancy for people living with HIV. Nearly 41 million people were living with HIV in 2024. Eastern ...
Dec 1, 2025
0
14
The rate of HIV infection continues to climb globally. Around 40 million people live with HIV-1, the most common HIV strain. While symptoms can now be better managed with lifelong treatment, there is no cure to fully eliminate ...
Oct 24, 2025
0
57
Results from a new trial published in The Lancet Global Health show that a mobile application, Med Safety, improved the reporting of suspected adverse drug reactions (ADRs) by health care workers in Uganda.
Sep 18, 2025
0
10
Around 10 million people globally live with the life-threatening virus HTLV-1. Yet it remains a poorly understood disease that currently has no preventative treatments and no cure.
Jul 22, 2025
0
35
The Global Fund announced Wednesday a deal with generic pharmaceutical manufacturers to significantly slash the price of a cutting-edge HIV drug, in a move it said would save lives.
Aug 30, 2023
0
81
Researchers at the University of Colorado Anschutz Medical Campus have helped confirm the dosing, safety and effectiveness of a drug formulation designed for treating children with human immunodeficiency virus (HIV).
Aug 2, 2023
0
109
Salk Institute researchers, in collaboration with the National Institutes of Health, have discovered the molecular mechanisms by which the human immunodeficiency virus (HIV) becomes resistant to Dolutegravir, one of the most ...
Jul 21, 2023
0
101
For patients with HIV without genotype information, a second-line switch to dolutegravir is noninferior to a regimen containing a ritonavir-boosted protease inhibitor (PI), according to a study published in the June 22 issue ...
Jun 23, 2023
0
60
For Black patients with HIV on antiretroviral therapy (ART), those who switch from efavirenz to dolutegravir gain more weight and have an increased risk for hypertension, according to a study published in the March issue ...
Mar 21, 2023
0
74
In 2019, the World Health Organization formally recommended the drug dolutegravir (DTG) as the preferred antiretroviral therapy (ART) for people living with HIV in low and middle-income countries (LMICs), citing that it is ...
Feb 22, 2023
0
70
